FacebookTwitterGoogle+Pinterest Invitrocue signs technology development agreement to include indications for multiple breast cancer subtypes. – Invitrocue to develop new breast cancer models for Onco-PDO TM that will include leading breast cancer subtypes ER+, PR+, HER2+ and Triple Negative Breast Cancer January 23, 2019 – Invitrocue Limited (ASX: IVQ), a leading … Continue reading Invitrocue Signs Technology Development Agreement